Therefore, our study aims to evaluate the effects of TAVR on cardiac function among severe AS patients with different phenotypes of HF, accessing by echocardiographic parameters, B-type natriuretic peptide (BNP) level and New York Heart Association (NYHA) class. This evidence concerns the gene NPPB and hydrops fetalis.